Navigation Links
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Date:5/8/2008

ate Phase 2 trials of BSI-201, reflecting the breadth of tumor types that could be sensitive to the drug."

The company is currently conducting a Phase 2 trial of BSI-201 in triple- negative breast cancer and is collaborating with the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group, to test BSI-201 in glioblastoma multiforme (GBM), the most common brain cancer in adults. An additional trial in uterine cancer is expected to begin enrollment in the coming weeks. The company also plans to present data from its Phase 1 trials of BSI-201 in solid tumors at the American Society of Clinical Oncology Annual Meeting that begins later this month in Chicago.

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
7. Neurocrine Biosciences Reports First Quarter 2008 Results
8. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
9. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...tCall/ -- Boston Scientific Corporation (NYSE: BS...nt in principle with the U.S. Department of Justic...s Guidant subsidiary in 2005. The alleged conduct...ific,s 2006 acquisition of Guidant. ,, Boston S...n by the U.S. Attorney,s Office in Minneapolis int...
(Date:11/6/2009)...l/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ), a ...f small-molecule therapeutics for the treatment of...V), today reported recent accomplishments and fina...s ended September 30, 2009. ,, (Logo: http:/... ,, "Since our last quarterly update, we have c...
(Date:11/6/2009)... -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) ...opharmaceutical company developing human vaccines ...cy Virus) and other infectious agents, today annou...provided an operational update. ,, Robert McNal...ommented, "We are pleased with our progress during...
Breaking Medicine Technology:Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 2Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 3Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 4Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 5Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 6Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 7Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 8Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 9Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 10Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 11Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 12Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 13Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 14Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 15Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 16Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant 17Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Underweight and Extremely Obese Die Earlier Than People of Normal Weight Study Finds 49807 1Underweight and Extremely Obese Die Earlier Than People of Normal Weight Study Finds 49807 2Underweight and Extremely Obese Die Earlier Than People of Normal Weight Study Finds 49807 3Underweight and Extremely Obese Die Earlier Than People of Normal Weight Study Finds 49807 4Determining Who Will Respond to Brain Tumor Therapy 49802 1A Canada wide technology platform for mapping the human interactome 8974 1A Canada wide technology platform for mapping the human interactome 8974 2
...HINGTON, Oct. 22 Today, the American,Society of H...al Oncology,(ASCO) have released an updated joint ... agents (ESAs), a class of drugs that stimulate,th...treat,chemotherapy-related anemia., "One goal of ...most,up-to-date evidence from high-quality studies...
...ICIA, Calif., Oct. 22 AcroMetrix, the leading,pro...agnostic and blood,testing laboratories, announced...ntification Panel to be the first to utilize an ED...is for Research Use Only, not for use in,diagnosti... allows the OptiQuant HIV-1 panel to,most closely ...
Other Medicine Technology:ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 2ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients 3AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel 2
(Date:11/7/2009)...swire-USNewswire/ -- Karen Ignagni, President and ...leased the following statement today on House pass...port comprehensive health care reform, and we have...plete overhaul of how health insurance is provided...ge, elimination of pre-existing condition exclusio...
(Date:11/7/2009)...ire-USNewswire/ -- The American Medical Associatio... for Citizenship and Community Service to Manus C.... The award recognizes physicians who have gone abo...ake an outstanding public service contribution to ...d today during the opening session of the 2009 Int...
(Date:11/7/2009)...), David A. Cook (GA), Louis J. Goodman (TX), Palm..., CHICAGO, Nov. 7 The...d five medical society executive leaders with achi... goals and ideals of the medical profession. The a...cy making meeting in Houston. ,, (Logo: http...
(Date:11/7/2009)...re-USNewswire/ -- Members of the AMA are trying a ...ution rescinding the AMA,s support of HR 3962. ,...sponsible to their PATIENTS, not the leadership of... for the Association of American Physicians and Su...er medical groups. ,, "If the AMA leadership i...
(Date:11/7/2009)...ics have a responsibility to vigorously oppose abo..." ,, WASHINGTON, Nov. 7 /PRNewswire-USNewsw...n released the following statement on the news tha...y Pelosi,s Affordable Health Care for America Act ...status quo for abortion is voted upon. ,, "Our...
Breaking Medicine News(10 mins):Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:AMA Honors Medical Society Executives 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2
...ch day more consumers are turning to webLAB to sav...tests online. Physicians Wellness Network (PWN) t... and trend their webLAB test results in their Micr...ation. , Jackson, WY (PRW...
...re-FirstCall/ - Transition Therapeutics Inc. ("Tra...H) announced today that the first patient has been...223 in combination with a proprietary Lilly GLP-1 ...e the safety, tolerability and efficacy of daily T...
...s to tell the story of leader in senior assisted l...e Highlands , the largest Continuing Care Retireme... WordWrite Communications as its agency of record... the quality living alternatives and services Reds...
...oRelix, pioneers in the discovery and development ... Medicinal Chemistry have jointly announced an exp...llaboration and agreement to discover and develop ...opment of Riboswitch based therapeutic agents, and...
...gent care provider NextCare continues its commitme...communities from six immediate care clinic locatio... March 23, 2009 -- Urgent care provider NextCare (... a location in Highlands Ranch coming in June, Nex...
...Telecare Corporation has appointed Pat Doyle to Vi...s new position, Doyle will focus on expanding Tele...managing acute psychiatric care services. Prior t...t Horizon Health Corporation. , , "Hospitals fre...
Other Medicine News:Health News:PWN Announces That Consumers Can Now Store webLAB Test Results In Their Microsoft HealthVault Account 2Health News:PWN Announces That Consumers Can Now Store webLAB Test Results In Their Microsoft HealthVault Account 3Health News:Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes 2Health News:Redstone Highlands Names WordWrite Communications Agency of Record 2Health News:BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches 2Health News:Three New NextCare Immediate Care Clinic Locations Open in Colorado 2
SPIRAL-FLEX® Reinforced Oral/Nasal Cuffed Endotracheal Tubes
... Endotracheal Tubes offer the features needed by t...ctile feedback from pilot balloon , Thermosensitiv...e , Smooth tube tip, molded and gently cupped to m...ff types: High Volume Tapered (HVT) and Close Fitt...
Bougie - Disposable
Microcuff Adult (ICU) Tracheal Tubes
Medicine Products: